Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?

This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 participants will be randomly assigned to receive either this combo or the laser plus standard chemotherapy. The goal is to see if the immunotherapy combo improves survival at 6 and 18 months.